New Developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 1

The following is a guest post from Sally Church (known to many in the twittersphere as @MaverickNY), from the Pharma Strategy Blog. The cancer research conference season kicked off in earnest in 2013 with the American Society of Clinical Oncology (ASCO)’s Gastrointestinal Symposium, held in San Francisco in late January. Some of the most anticipated data to be presented at ASCO GI was for drugs that treat pancreatic cancer, with three...

Read More

Epizyme & Celgene to Develop Epigenetics-Based Cancer Drugs

Cambridge, Mass.-based Epizyme has scored $90 million upfront as part of a broad cancer drug development pact with Celgene. The deal adds to a spate of lucrative pacts to find compounds to modulate epigenetic targets, or enzymes that control gene expression without altering the underlying DNA. As we wrote in last week’s cover story, DNA carries the instructions for assembling all of life’s essential building blocks, but epigenetics...

Read More

Celgene & Avila Forge Permanent Ties

Today brought a spate of M&A activity in the biotech space, with Amgen unveiling a $1.2 billion bid for Micromet, and Celgene agreeing to pay up to $925 million for Avila Therapeutics. Both deals brought the acquirer a drug in development to treat blood cancers, while also adding a platform technology to their research engines. Being all about the chemistry, The Haystack is particularly interested in the Celgene/Avila deal, which...

Read More

Celgene Goes After Cancer’s Achilles’ Heel

The drug industry seems to be coming back around to the idea that cancer has an Achilles’ heel. In the latest deal related to cancer metabolism, Celgene is handing over $130 million upfront for access to oncology drugs coming out of Agios Pharmaceuticals‘ labs. Under the pact, Celgene, for a period of time, can opt-in on any drug candidate generated by Agios’ cell metabolism technology. Celgene can also put up extra cash...

Read More